Telescope InnovationsTELIF -0.21%27 PS Ratio is 6.06 as of Jul. 06, 2026, which is 28% above its 10-year median of 4.74. GuruFocus rates TELIF with a GF Score™ of 27/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 929 Biotechnology companies, Telescope Innovations ranks better than 62% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Telescope Innovations's share price is $0.509.
Telescope Innovations's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was $0.08. Hence, Telescope Innovations's PS Ratio for today is 6.06.
The historical rank and industry rank for Telescope Innovations's PS Ratio or its related term are showing as below:
TELIF'
s PS Ratio Range Over the Past 10 Years
Min: 2.47 Med: 4.74 Max: 25.83
Current: 6.12
During the past 7 years, Telescope Innovations's highest PS Ratio was 25.83. The lowest was 2.47. And the median was 4.74.
TELIF's PS Ratio is ranked better than 62% of 929
companies
in the Biotechnology industry
Industry Median: 9.91
vs TELIF: 6.12
During the past 7 years, Telescope Innovations's highest 3-Year average Revenue per Share Growth Rate was 95.00% per year. The lowest was 95.00% per year. And the median was 95.00% per year.
Back to Basics: PS Ratio
Telescope Innovations (OTCPK:TELIF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Telescope Innovations's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's PS Ratio distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Telescope Innovations's Share Price of today is $0.509. Telescope Innovations's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Telescope Innovations (TELIF) has a PS Ratio of 6.06 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Telescope Innovations and its competitors. This is 28% above median its historical median of 4.74. Over the past decade, Telescope Innovations' PS Ratio has ranged from 2.47 to 25.83. According to the industry distribution chart, Telescope Innovations ranks #353 out of 929 companies in the Biotechnology industry, placing it in the top 38%.
Is Telescope Innovations' PS Ratio too high?
Telescope Innovations' current PS Ratio of 6.06 is 28% above median its 10-year median of 4.74. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 25.83. The Biotechnology industry median PS Ratio is 9.91. Telescope Innovations' value of 6.06 is 38.8% below this industry median. Based on the distribution chart, Telescope Innovations ranks #353 out of 929 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Telescope Innovations has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #353 out of 929 companies for PS Ratio. This puts Telescope Innovations in the upper half of its industry. The industry median PS Ratio is 9.91. Telescope Innovations' value of 6.06 is 38.8% below this benchmark. Historically, Telescope Innovations' own PS Ratio has ranged from 2.47 to 25.83 over the past decade. While the company's 10-year median is 4.74 vs. the industry median of 9.91, Telescope Innovations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.91, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telescope Innovations's current PS Ratio of 6.06 is 38.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Telescope Innovations and its competitors. For the Biotechnology industry, the median PS Ratio is 9.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telescope Innovations's current PS Ratio is 6.06, which is 28% above median its own 10-year median of 4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.51 — trading 33.9% above its estimated fair value. The current PS Ratio is 6.06, which is 28% above median its 10-year median of 4.74 and 38.8% below the Biotechnology industry median of 9.91. Telescope Innovations' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current PS Ratio is 6.06 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be overvalued.
The current stock price of $0.51 is trading 33.9% above its estimated GF Value™ of $0.38.
GuruFocus considers Telescope Innovations to be Significantly Overvalued.
Key valuation signals for TELIF:
PS Ratio: 6.06 (28% above median its 10-year median of 4.74)
GF Value™: $0.38 vs. price of $0.51 (33.9% above fair value)
Industry Position: 38.8% below the Biotechnology median (#353 of 929)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
27GF Score
Get the complete analysis for TELIF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
